It's interesting what ChatGPT puts forth about combining CORE-NK and Pomalidomide with Vactrosertib and its potential significance for solid tumours.
This is the area where CHM is being positioned within the immunotherapy space. Merck's patent for Keytruda runs out in 2028. The cost of treating the side effects of chemo is a real burden to economies. There is likely never going to be a blockbuster miracle cure for cancer but immunotherapy will give patients quality of life while being treated with the right combo of therapies.
Ann: AML patient achieves Complete Response in CHM CORE-NK trial, page-57
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.045M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $22.28K | 6.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 84735861 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86304338 | 23 |
View Market Depth
| Last trade - 14.27pm 25/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |